Transcode Therapeutics (RNAZ) Price to Book (2021 - 2026)

Transcode Therapeutics (RNAZ) has reported Price to Book for 6 consecutive years, with 0.23 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 121.44% year-over-year to 0.23; the trailing twelve-month figure through Jun 2026 stood at 0.23 (down 121.44% YoY), and the FY2025 full-year result was 0.46, up 102.74% from the prior year.
• Price to Book eased to 0.23 in Q2 2026 per RNAZ's latest filing, from 6.31 in the prior quarter.
• Across five years, Price to Book topped out at 3018.17 in Q4 2022 and bottomed at 25369.8 in Q1 2023.
• Historically, Price to Book has averaged 782.35 across 5 years, with a median of 22.19 in 2023.
• The sharpest annual moves came in 2022 and 2023: Price to Book soared 156.95% in 2022, then sank 1130.45% in 2023.
• Over 5 years, Price to Book stood at 3018.17 in 2022, then plunged by 99.33% to 20.16 in 2023, then plunged by 182.57% to 16.65 in 2024, then surged by 102.74% to 0.46 in 2025, then slumped by 149.77% to 0.23 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 0.23, 6.31, and 0.46 for Q2 2026, Q1 2026, and Q4 2025 respectively.